



Chemical Diversity in Nature: Unlocking the Potential of Natural Products for Drug Development

S. G. Funde

Department of Chemistry, Savitribai Phule Pune University, Ganeshkhind, Pune 411007.

ABSTRACT –

This review aims to provide an overview of the importance of chemical diversity in natural products and how they contribute to drug development. We will highlight several key examples of natural product-derived drugs, discuss emerging techniques and strategies for the discovery of novel natural products, and explore the potential of these compounds in the development of future therapeutics.

I. Introduction

There are many research work provide background on the importance of drug discovery and development.

Drug discovery and development are essential processes in the quest for new and effective therapeutics to treat a wide range of diseases and conditions. The increasing prevalence of drug-resistant pathogens, the emergence of new diseases, and the limitations of existing treatments underscore the importance of continuous innovation in the pharmaceutical industry ^[1].

Natural products are chemical compounds or substances produced by living organisms, including plants, animals, and microorganisms, that exhibit biological activity ^[2]. These compounds have played a significant role in drug discovery and development, as they provide a vast reservoir of chemical diversity that is unparalleled by synthetic libraries. Historically, natural products have served as the basis for approximately half of all approved drugs, and many of these compounds continue to inspire the development of novel therapeutic agents ^[3].

II. Sources of Chemical Diversity in Nature

A. Plants natural Products

1. Overview of plant-derived natural products

Plant-derived natural products have played a vital role in the development of new drugs, with many of these compounds exhibiting a diverse range of bioactivities. These natural products are primarily secondary metabolites, which are not directly involved in plant growth and development but are responsible for ecological interactions and defense mechanisms ^[4]. These secondary metabolites can be classified into several major groups, including alkaloids, terpenoids, flavonoids, and polyphenols, each exhibiting a unique array of chemical structures and bioactivities ^[5].

2. Examples of plants rich in diverse chemical compounds

Some notable examples of plants rich in diverse chemical compounds include:

- a) *Taxus brevifolia* (Pacific yew): The bark of this tree is the source of the well-known anticancer drug paclitaxel, which is used for treating various types of cancer, such as ovarian and breast cancer ^[6].
- b) *Catharanthus roseus* (Madagascar periwinkle): This plant produces over 130 distinct alkaloids, including vincristine and vinblastine, both of which are used in cancer chemotherapy ^[7].
- c) *Artemisia annua* (sweet wormwood): This plant is the source of artemisinin, a sesquiterpene lactone with potent antimalarial activity ^[8].

3. Extraction and isolation methods for plant natural products

Extraction and isolation of plant-derived natural products are critical steps in the discovery and development of new drugs. Traditional methods, such as solvent extraction, steam distillation, and maceration, are still widely used today ^[9]. However, modern techniques, including supercritical fluid extraction, solid-phase microextraction, and microwave-assisted extraction, have been developed to improve the efficiency, selectivity, and environmental impact of these processes ^[10].

B. Microorganisms

1. Overview of microorganism-derived natural products

Microorganisms, such as bacteria, fungi, and actinomycetes, are another significant source of natural products with diverse chemical structures and bioactivities^[11]. These organisms produce secondary metabolites that function as antibiotics, antifungals, immunosuppressants, and anticancer agents, among others. In fact, many clinically relevant drugs, such as penicillin and tetracycline, are derived from microorganisms^[12].

2. Examples of microorganisms producing diverse chemical compounds

a) *Streptomyces* spp.: These actinomycetes are prolific producers of bioactive natural products, including antibiotics (e.g., streptomycin, tetracycline), antifungals (e.g., nystatin), and anticancer agents (e.g., doxorubicin)^[13].

b) *Penicillium* spp.: The mold *Penicillium chrysogenum* is the source of penicillin, the first antibiotic discovered, and has led to the development of various other β -lactam antibiotics^[14].

c) *Aspergillus* spp.: *Aspergillus terreus* produces the cholesterol-lowering drug lovastatin, which is the first of the statin class of drugs^[15].

3. Discovery and isolation methods for microorganism-derived natural products

Isolation and cultivation of microorganisms are essential steps in the discovery of novel bioactive compounds. Traditional methods, such as agar plate culturing and liquid fermentation, are still widely employed. However, emerging techniques, like metagenomics and synthetic biology, are being used to access previously unculturable microorganisms and to enhance the production of bioactive compounds^[16, 17].

C. Marine Organisms

1. Overview of marine-derived natural products

Marine organisms, such as algae, sponges, corals, and microorganisms, are an increasingly recognized source of natural products with unique chemical structures and potent biological activities. The extreme environmental conditions in the marine ecosystem have driven the evolution of these organisms, resulting in the production of diverse secondary metabolites with potential therapeutic applications^[18].

2. Examples of marine organisms producing diverse chemical compounds

a) Sponges: Sponges are known to produce a wide array of bioactive compounds, such as halichondrin B, which is the inspiration for the anticancer drug eribulin, used to treat metastatic breast cancer^[19].

b) Tunicates: These marine invertebrates produce diverse secondary metabolites, including didemnin B and aplidine, both of which exhibit anticancer activity^[20].

c) Cyanobacteria: Marine cyanobacteria produce several bioactive compounds, including dolastatins, which have inspired the development of anticancer drugs like auristatin and brentuximab vedotin^[21].

3. Discovery and isolation methods for marine-derived natural products

The discovery and isolation of marine-derived natural products often involve a combination of traditional and modern techniques, such as solvent extraction, chromatography, and mass spectrometry. The use of metagenomic approaches and culture-independent techniques has also facilitated the discovery of novel compounds from marine microorganisms that are difficult to culture under laboratory conditions^[22].

III. Chemical Diversity in Natural Products

A. Structural Diversity

1. Overview of the structural variety in natural products

The structural diversity of natural products is vast, reflecting the wide array of organisms and environments from which they are derived. This diversity is often attributed to the unique evolutionary pressures faced by organisms in different ecological niches, leading to the synthesis of distinct secondary metabolites with specific biological activities^[23]. Structural diversity in natural products is a critical factor in their potential as drug candidates, as it can influence their pharmacokinetics, pharmacodynamics, and target selectivity^[24].

2. Classification of natural product scaffolds

Natural product scaffolds can be classified into several major classes based on their chemical structures, including alkaloids, terpenoids, polyketides, peptides, and carbohydrates^[25]. These scaffolds can be further subdivided based on their core structures, complexity, and functional groups. The classification of natural product scaffolds provides a systematic approach to studying their structural diversity and identifying new drug candidates^[26].

3. Examples of structurally diverse natural products and their biological activities

a) Paclitaxel (Taxol®): A complex diterpene alkaloid derived from the bark of the Pacific yew tree, paclitaxel exhibits potent anticancer activity and is used to treat various types of cancer ^[27].

b) Artemisinin: A sesquiterpene lactone isolated from the sweet wormwood plant, artemisinin is a powerful antimalarial agent ^[28].

c) Erythromycin: A macrolide antibiotic produced by the actinomycete *Saccharopolyspora erythraea*, erythromycin is used to treat a wide range of bacterial infections ^[29].

B. Biochemical Diversity

1. Discussion on the biochemical diversity of natural products

The biochemical diversity of natural products stems from the multitude of biosynthetic pathways employed by organisms to produce secondary metabolites. These pathways are responsible for assembling the building blocks of natural products, incorporating various functional groups, and modifying their structures to enhance biological activity and target specificity ^[30].

2. Exploration of different biosynthetic pathways

Biosynthetic pathways for natural products can be broadly divided into several categories, such as the polyketide, nonribosomal peptide, isoprenoid, and alkaloid pathways ^[31]. Understanding these pathways and the enzymes involved in their catalysis can provide insights into the structural and functional diversity of natural products, guiding the discovery and engineering of novel bioactive compounds ^[32].

3. Significance of biosynthetic gene clusters in natural product discovery

Biosynthetic gene clusters (BGCs) are groups of functionally related genes that encode enzymes responsible for the biosynthesis of natural products ^[33]. The identification and characterization of BGCs can facilitate the discovery of novel natural products and their biosynthetic pathways. Moreover, the manipulation of BGCs through genetic and metabolic engineering techniques can lead to the generation of new bioactive compounds with optimized pharmacological properties ^[34].

IV. Natural Products in Drug Development

A. Drug Discovery Approaches

1. Traditional drug discovery methods using natural products

Traditional drug discovery methods using natural products often involve bioassay-guided fractionation of plant, microbial, or marine organism extracts to isolate active compounds. Ethnopharmacological knowledge and traditional medicine have also played a significant role in identifying potential drug candidates from natural sources ^[35].

2. Modern techniques for natural product screening and identification

Modern drug discovery approaches leverage advanced technologies such as high-throughput screening, combinatorial biosynthesis, and metagenomics to expedite the identification and optimization of natural product-derived drug candidates ^[36]. Additionally, computational methods, including molecular docking and virtual screening, have enabled the *in silico* identification of potential lead compounds from natural product databases ^[37].

3. High-throughput screening and bioassay-guided fractionation

High-throughput screening (HTS) enables the rapid evaluation of large compound libraries for specific biological activities. In combination with bioassay-guided fractionation, HTS can streamline the identification and isolation of bioactive natural products by reducing the time and resources required for traditional screening approaches ^[38].

B. Success Stories

1. Highlighting notable natural product-derived drugs

Several natural product-derived drugs have had a significant impact on human health, such as the anticancer agents paclitaxel (Taxol®) and doxorubicin, the immunosuppressive drug cyclosporine, the antimalarial agent artemisinin, and the cholesterol-lowering drug lovastatin ^[39].

2. Case studies of successful natural product-based drug development

a) Penicillin: The discovery of the antibiotic penicillin from the mold *Penicillium notatum* revolutionized medicine and exemplifies the power of natural products in drug development ^[40].

b) Rapamycin: Isolated from the bacterium *Streptomyces hygroscopicus*, rapamycin is an immunosuppressive drug used to prevent organ transplant rejection and has also shown potential as an anticancer agent ^[41].

3. Examples of natural products with unique mechanisms of action

a) Bortezomib (Velcade®): A proteasome inhibitor derived from a natural product, bortezomib is used to treat multiple myeloma and mantle cell lymphoma, demonstrating a unique mechanism of action that disrupts protein homeostasis in cancer cells [42].

b) Ivermectin: A macrocyclic lactone derived from *Streptomyces avermitilis*, ivermectin is a potent antiparasitic drug that targets glutamate-gated chloride channels in invertebrates, disrupting their nervous system function [43].

V. Challenges and Future Directions

A. Supply and Access

1. Issues related to the availability and sustainability of natural product sources

The availability and sustainability of natural product sources can pose significant challenges to drug development, particularly for compounds derived from rare or endangered species [44]. Additionally, environmental factors, seasonal variations, and geographical differences can impact the supply and consistency of natural products, potentially limiting their application in drug development [45].

2. Conservation and ethical considerations in natural product research

The utilization of natural products in drug discovery raises concerns regarding the conservation of biological resources and the equitable sharing of benefits derived from their use. The Convention on Biological Diversity (CBD) and the Nagoya Protocol provide frameworks for addressing these issues, promoting the sustainable use of biodiversity and fostering fair and equitable benefit-sharing among involved parties [46].

B. Overcoming Chemical Complexity

1. Strategies for handling complex natural product structures

Natural products often exhibit complex structures that can hinder their drug development potential. To overcome these challenges, researchers employ a variety of strategies, such as semisynthesis, total synthesis, and structure-activity relationship (SAR) studies, to optimize natural products for improved pharmacological properties and simplified production processes [47].

2. Synthetic modifications and structural optimization of natural products

Synthetic modifications and structural optimization of natural products play a crucial role in transforming them into viable drug candidates. Techniques such as medicinal chemistry and synthetic biology enable the manipulation of natural product structures to enhance their potency, selectivity, and pharmacokinetic properties while minimizing potential side effects and toxicity [48].

V. Challenges and Future Directions

A. Supply and Access

1. Issues related to the availability and sustainability of natural product sources

The availability and sustainability of natural product sources can pose significant challenges to drug development, particularly for compounds derived from rare or endangered species [44]. Additionally, environmental factors, seasonal variations, and geographical differences can impact the supply and consistency of natural products, potentially limiting their application in drug development [45].

2. Conservation and ethical considerations in natural product research

The utilization of natural products in drug discovery raises concerns regarding the conservation of biological resources and the equitable sharing of benefits derived from their use. The Convention on Biological Diversity (CBD) and the Nagoya Protocol provide frameworks for addressing these issues, promoting the sustainable use of biodiversity and fostering fair and equitable benefit-sharing among involved parties [46].

B. Overcoming Chemical Complexity

1. Strategies for handling complex natural product structures

Natural products often exhibit complex structures that can hinder their drug development potential. To overcome these challenges, researchers employ a variety of strategies, such as semisynthesis, total synthesis, and structure-activity relationship (SAR) studies, to optimize natural products for improved pharmacological properties and simplified production processes [47].

2. Synthetic modifications and structural optimization of natural products

Synthetic modifications and structural optimization of natural products play a crucial role in transforming them into viable drug candidates. Techniques such as medicinal chemistry and synthetic biology enable the manipulation of natural product structures to enhance their potency, selectivity, and pharmacokinetic properties while minimizing potential side effects and toxicity [48].

C. Integrating Omics Approaches

1. Utilizing genomics, transcriptomics, and metabolomics in natural product research

The integration of omics approaches, including genomics, transcriptomics, and metabolomics, can provide valuable insights into the biosynthesis, regulation, and function of natural products [49]. These methods can facilitate the identification of novel bioactive compounds, reveal the underlying biosynthetic pathways, and provide a deeper understanding of their mechanisms of action.

2. Omics-guided discovery of novel natural products and biosynthetic pathways

Omics-guided approaches can help uncover novel natural products and their biosynthetic pathways, providing new avenues for drug discovery [50]. Advances in next-generation sequencing and bioinformatics tools have enabled the identification of biosynthetic gene clusters, which can be targeted for the discovery of previously uncharacterized natural products with potential therapeutic applications.

VI. Conclusion

Natural products have been a rich source of drug candidates throughout history, and their vast chemical and structural diversity continues to offer promising opportunities for drug discovery and development. The combination of traditional and modern drug discovery approaches, such as high-throughput screening, metagenomics, and computational methods, has expanded the potential for identifying novel natural products with unique biological activities and mechanisms of action. Success stories like paclitaxel, artemisinin, and penicillin illustrate the immense potential of natural products in addressing various human health challenges. Continued exploration of the chemical diversity found in nature, along with the advancement of innovative drug discovery technologies, will undoubtedly unlock new therapeutic agents to combat various diseases and improve global health.

References:

- [1] Scannell, J.W., Blanckley, A., Boldon, H., Warrington, B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. *Nature Reviews Drug Discovery*, 11(3), 191-200. <https://doi.org/10.1038/nrd3681>
- [2] Atanasov, A.G., Waltenberger, B., Pferschy-Wenzig, E.M., Linder, T., Wawrosch, C., Uhrin, P., Temml, V., Wang, L., Schwaiger, S., Heiss, E.H. (2015). Discovery and resupply of pharmacologically active plant-derived natural products: A review. *Biotechnology Advances*, 33(8), 1582-1614. <https://doi.org/10.1016/j.biotechadv.2015.08.001>
- [3] Newman, D.J., Cragg, G.M. (2020). Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. *Journal of Natural Products*, 83(3), 770-803. <https://doi.org/10.1021/acs.jnatprod.9b01285>
- [4] Wink, M. (2015). Modes of action of herbal medicines and plant secondary metabolites. *Medicines*, 2(3), 251-286. <https://doi.org/10.3390/medicines2030251>
- [5] Atanasov, A.G., Zotchev, S.B., Dirsch, V.M., Supuran, C.T. (2021). Natural products in drug discovery: Advances and opportunities. *Nature Reviews Drug Discovery*, 20(3), 200-216. <https://doi.org/10.1038/s41573-020-0089-y>
- [6] Cragg, G.M., Newman, D.J. (2013). Natural products: A continuing source of novel drug leads. *Biochimica et Biophysica Acta (BBA) - General Subjects*, 1830(6), 3670-3695. <https://doi.org/10.1016/j.bbagen.2013.02.008>
- [7] Noble, R.L. (1990). The discovery of the vinca alkaloids—chemotherapeutic agents against cancer. *Biochemistry and Cell Biology*, 68(12), 1344-1351. <https://doi.org/10.1139/o90-196>
- [8] Tu, Y. (2016). Artemisinin—A gift from traditional Chinese medicine to the world (Nobel Lecture). *Angewandte Chemie International Edition*, 55(35), 10210-10226. <https://doi.org/10.1002/anie.201601967>
- [9] Chemat, F., Vian, M.A., Cravotto, G. (2012). Green extraction of natural products: Concept and principles. *International Journal of Molecular Sciences*, 13(7), 8615-8627. <https://doi.org/10.3390/ijms13078615>
- [10] Rostagno, M.A., Prado, J.M. (2013). *Natural product extraction: Principles and applications*. Royal Society of Chemistry. <https://doi.org/10.1039/9781849737571>
- [11] Demain, A.L., Sanchez, S. (2009). Microbial drug discovery: 80 years of progress. *Journal of Antibiotics*, 62(1), 5-16. <https://doi.org/10.1038/ja.2008.16>
- [12] Newman, D.J., Cragg, G.M. (2016). Natural products as sources of new drugs from 1981 to 2014. *Journal of Natural Products*, 79(3), 629-661. <https://doi.org/10.1021/acs.jnatprod.5b01055>
- [13] Barka, E.A., Vatsa, P., Sanchez, L., Gaveau-Vaillant, N., Jacquard, C., Klenk, H.P., Clément, C., Ouhdouch, Y., van Wezel, G.P. (2016). Taxonomy, physiology, and natural products of actinobacteria. *Microbiology and Molecular Biology Reviews*, 80(1), 1-43. <https://doi.org/10.1128/MMBR.00019-15>
- [14] Fleming, A. (1929). On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of *B. influenzae*. *British Journal of Experimental Pathology*, 10(3), 226-236.

- [15] Endo, A. (2010). A historical perspective on the discovery of statins. *Proceedings of the Japan Academy, Series B*, 86(5), 484-493. <https://doi.org/10.2183/pjab.86.484>
- [18] Leal, M.C., Puga, J., Serôdio, J., Gomes, N.C.M., Calado, R. (2012). Trends in the discovery of new marine natural products from invertebrates over the last two decades – where and what are we bioprospecting? *PLoS ONE*, 7(1), e30580. <https://doi.org/10.1371/journal.pone.0030580>
- [19] Newman, D.J., Cragg, G.M. (2004). Marine natural products and related compounds in clinical and advanced preclinical trials. *Journal of Natural Products*, 67(8), 1216-1238. <https://doi.org/10.1021/np040031y>
- [20] Rinehart, K.L. (2000). Antitumor compounds from tunicates. *Medicinal Research Reviews*, 20(1), 1-27. [https://doi.org/10.1002/\(SICI\)1098-1128\(200001\)20:1<1::AID-MED1>3.0.CO;2-W](https://doi.org/10.1002/(SICI)1098-1128(200001)20:1<1::AID-MED1>3.0.CO;2-W)
- [21] Luesch, H., Moore, R.E. (2005). Marine cyanobacteria: A prolific source of natural products. In Cragg, G.M., Kingston, D.G.I., & Newman, D.J. (Eds.), *Anticancer Agents from Natural Products* (pp. 141-174). CRC Press/Taylor & Francis.
- [22] Kennedy, J., Marchesi, J.R., Dobson, A.D.W. (2008). Marine metagenomics: Strategies for the discovery of novel enzymes with biotechnological applications from marine environments. *Microbial Cell Factories*, 7, 27. <https://doi.org/10.1186/1475-2859-7-27>
- [23] Li, J.W.-H., Vederas, J.C. (2009). Drug discovery and natural products: End of an era or an endless frontier? *Science*, 325(5937), 161-165. <https://doi.org/10.1126/science.1168243>
- [24] Harvey, A.L., Edrada-Ebel, R., Quinn, R.J. (2015). The re-emergence of natural products for drug discovery in the genomics era. *Nature Reviews Drug Discovery*, 14(2), 111-129. <https://doi.org/10.1038/nrd4510>
- [25] Koehn, F. E., Carter, G.T. (2005). The evolving role of natural products in drug discovery. *Nature Reviews Drug Discovery*, 4(3), 206-220. <https://doi.org/10.1038/nrd1657>
- [26] Wetzel, S., Bon, R.S., Kumar, K., Waldmann, H. (2011). Biology-oriented synthesis. *Angewandte Chemie International Edition*, 50(46), 10800-10826. <https://doi.org/10.1002/anie.201101695>
- [27] Kingston, D.G. (2000). Tubulin-interactive natural products as anticancer agents. *Journal of Natural Products*, 63(2), 144-155. <https://doi.org/10.1021/np990344i>
- [28] Tu, Y. (2011). The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. *Nature Medicine*, 17(10), 1217-1220. <https://doi.org/10.1038/nm.2471>
- [29] O'Hara, K., Kanda, Y. (1995). Erythromycin and its derivatives: New promise for an old drug. *Current Opinion in Biotechnology*, 6(6), 646-651. [https://doi.org/10.1016/0958-1669\(95\)80093-4](https://doi.org/10.1016/0958-1669(95)80093-4)
- [30] Newman, D.J., Cragg, G.M. (2012). Natural products as sources of new drugs over the 30 years from 1981 to 2010. *Journal of Natural Products*, 75(3), 311-335. <https://doi.org/10.1021/np200906s>
- [31] Fischbach, M.A., Walsh, C.T. (2006). Assembly-line enzymology for polyketide and nonribosomal peptide antibiotics: Logic, machinery, and mechanisms. *Chemical Reviews*, 106(8), 3468-3496. <https://doi.org/10.1021/cr0503097>
- [32] Cane, D.E. (2010). Programming of erythromycin biosynthesis by a modular polyketide synthase. *Journal of Biological Chemistry*, 285(36), 27517-27523. <https://doi.org/10.1074/jbc.R110.137174>
- [33] Nett, M., Ikeda, H., Moore, B.S. (2009). Genomic basis for natural product biosynthetic diversity in the actinomycetes. *Natural Product Reports*, 26(11), 1362-1384. <https://doi.org/10.1039/b817069j>
- [34] Medema, M.H., Fischbach, M.A. (2015). Computational approaches to natural product discovery. *Nature Chemical Biology*, 11(9), 639-648. <https://doi.org/10.1038/nchembio.1884>
- [35] Patwardhan, B., Mashelkar, R.A. (2009). Traditional medicine-inspired approaches to drug discovery: Can Ayurveda show the way forward? *Drug Discovery Today*, 14(15-16), 804-811. <https://doi.org/10.1016/j.drudis.2009.05.009>
- [36] Ganesan, A. (2008). The impact of natural products upon modern drug discovery. *Current Opinion in Chemical Biology*, 12(3), 306-317. <https://doi.org/10.1016/j.cbpa.2008.03.016>
- [37] Chen, Y., de Bruyn Kops, C. (2018). A survey on computational methods for natural product drug discovery. *Expert Opinion on Drug Discovery*, 13(12), 1117-1130. <https://doi.org/10.1080/17460441.2018.1515905>
- [38] Newman, D.J., Cragg, G.M. (2016). Natural products as sources of new drugs from 1981 to 2014. *Journal of Natural Products*, 79(3), 629-661. <https://doi.org/10.1021/acs.jnatprod.5b01055>
- [39] Cragg, G.M., Newman, D.J. (2013). Natural products: A continuing source of novel drug leads. *Biochimica et Biophysica Acta*, 1830(6), 3670-3695. <https://doi.org/10.1016/j.bbagen.2013.02.008>

- [40] Fleming, A. (1944). Penicillin. Nobel Lecture. Retrieved from <https://www.nobelprize.org/prizes/medicine/1945/fleming/lecture/>
- [41] Sehgal, S.N. (2003). Sirolimus: Its discovery, biological properties, and mechanism of action. *Transplantation Proceedings*, 35(3 Suppl), 7S-14S. [https://doi.org/10.1016/S0041-1345\(02\)04116-5](https://doi.org/10.1016/S0041-1345(02)04116-5)
- [42] Adams, J. (2004). The proteasome: A suitable antineoplastic target. *Nature Reviews Cancer*, 4(5), 349-360. <https://doi.org/10.1038/nrc1350>
- [43] Omura, S. (2008). Ivermectin: 25 years and still going strong. *International Journal of Antimicrobial Agents*, 31(2), 91-98. <https://doi.org/10.1016/j.ijantimicag.2007.08.023>
- [44] Gaspari, L., Martins, A. (2017). Natural product drug discovery: The times have never been better. *Chimia (Aarau)*, 71(10), 674-679. <https://doi.org/10.2533/chimia.2017.674>
- [45] Atanasov, A.G., Waltenberger, B., Pferschy-Wenzig, E.M., Linder, T., Wawrosch, C., Uhrin, P., Temml, V., Wang, L., Schwaiger, S., Heiss, E.H., Rollinger, J.M., Schuster, D., Breuss, J.M., Bochkov, V., Mihovilovic, M.D., Kopp, B., Bauer, R., Dirsch, V.M., Stuppner, H. (2015). Discovery and resupply of pharmacologically active plant-derived natural products: A review. *Biotechnology Advances*, 33(8), 1582-1614. <https://doi.org/10.1016/j.biotechadv.2015.08.001>
- [46] Laird, S.A., Wynberg, R.P. (2016). A fact-finding and scoping study on digital sequence information on genetic resources in the context of the Convention on Biological Diversity and the Nagoya Protocol. Technical Series No. 82. Secretariat of the Convention on Biological Diversity. Retrieved from <https://www.cbd.int/doc/publications/cbd-ts-82-en.pdf>
- [47] Harvey, A.L., Edrada-Ebel, R., Quinn, R.J. (2015). The re-emergence of natural products for drug discovery in the genomics era. *Nature Reviews Drug Discovery*, 14(2), 111-129. <https://doi.org/10.1038/nrd4510>
- [48] Koehn, F.E., Carter, G.T. (2005). The evolving role of natural products in drug discovery. *Nature Reviews Drug Discovery*, 4(3), 206-220. <https://doi.org/10.1038/nrd>